Bayer
Bayer is a global enterprise with core competencies in the fields of health care, agriculture and high-tech polymer materials. As an innovation company, it sets trends in research-intensive areas. Bayer's products and services are designed to benefit people and improve their quality of life. At the same time, the Group aims to create value through innovation, growth and high earning power. Bayer is committed to the principles of sustainable development and to its social and ethical responsibilities as a corporate citizen. In fiscal 2014, the Group employed 118,900 people and had sales of EUR 42.2 billion. Capital expenditures amounted to EUR 2.5 billion, R&D expenses to EUR 3.6 billion.
Business & Industry
- Pfizer and BioNTech report new data on Omicron BA.4/BA.5-adapted bivalent booster
- GSK announces positive Phase IIa study results for a new first-in-class candidate medicine for patients with tuberculosis
- Sanofi and GSK's next-generation COVID-19 booster vaccine VidPrevtyn® Beta approved by the European Commission
- Pfizer and BioNTech receive positive CHMP opinion for Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine booster for children 5 through 11 years of age in European Union
- Vividion Therapeutics names Jenna Goldberg as Chief Medical Officer
Research & Development
- AI tailors artificial DNA for future drug development
- Remdesivir reduces COVID-19 mortality in a real-world setting
- Pocket feature shared by deadly coronaviruses could lead to pan-coronavirus antiviral treatment
- Cryptic drug-binding sites discovered in the dance
- Unusual type of antibody shows ultrapotent activity against Zika
- Machine learning can help predict patient response to cancer immunotherapy
- New drug shows promise for fighting both COVID-19 and cancer
Conferences & Events
- CPHI Excellence in Pharma Award Winners 2022
- CPHI Frankfurt Report predicts huge funding overhang to drive contract services growth
- CPHI Frankfurt 2022: Global pharma confidence hits record high in the annual CPHI Pharma Index
- SAE Media Group proudly presents the 2nd Annual Aseptic Processing Conference
- Pharma join together to achieve new standards in digital and patient innovation for clinical transformation
- SMi's 22nd Annual Pain Therapeutics Conference
- SMi Group Introduces the 4th Annual Injectable Drug Delivery Conference 2022
Regulatory Affairs
- FDA approves first gene therapy to treat adults with Hemophilia B
- FDA approves first treatment for Acid Sphingomyelinase Deficiency, a rare genetic disease
- FDA approves first systemic treatment for alopecia areata
- FDA urges drug manufacturers to develop risk management plans to promote a dtronger, resilient drug supply chain
- FDA limits use of Janssen COVID-19 vaccine to certain individuals